Our interest in neonatal pediatric screening is enhanced by the introduction of new molecular techniques. We are launching a new service, RARE-iD, which undertakes to offer children with serious diseases the most complete molecular tests such as Whole Genome Sequencing, Whole Exome Sequencing, High Resolution Molecular Karyotype, at a cost commensurate with the cost currently paid by parents for obsolete molecular controls. This RARE-iD service has been funded by the NSRF with 997,000 euros to offer FREE the above extended genetic tests to children with rare neurodevelopmental diseases and autism. In the project we collaborate with important bodies such as the University Hospital Attiko and Professor Mr. Dinopoulos Argyris, the speech therapy company Habilis, the Athens School of Pharmacy.